Pharvaris N.V. (PHVS) — SEC Filings

Latest SEC filings for Pharvaris N.V. (PHVS), explained in plain English.

Sentiment Overview: 2 bearish, 34 neutral

Recent Filings (36)

• Pharvaris N.V. Files 2025 Annual Report, Maintains Foreign Issuer Status — 20-F · 2026-04-02T06:51:25-04:00 [neutral] Risk: low
  Pharvaris N.V. filed its 20-F for the period ending December 31, 2025, indicating its ongoing status as a foreign private issuer. The filing itself does not con
• 6-K Filing — 6-K · 2026-04-02T06:50:02-04:00 [neutral]
• 6-K Filing — 6-K · 2025-12-03T00:00:00.000Z [neutral]
• Pharvaris N.V. Files Routine 6-K Report — 6-K · 2025-11-12T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on November 12, 2025, reporting for the month of November 2025. The company, previously known as Pharvaris, B.V., is a foreign p
• Pharvaris N.V. Files Routine 6-K Report — 6-K · 2025-09-08T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on September 8, 2025, reporting for the month of September 2025. The company, previously known as Pharvaris, B.V., is a foreign
• Pharvaris N.V. Files 6-K for Q2 2025 — 6-K · 2025-08-12T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a 6-K report on August 12, 2025, for the period ending June 30, 2025. The filing includes financial data such as gross carrying amounts and
• Pharvaris N.V. Files 6-K, Reports Under Form 20-F — 6-K · 2025-07-24T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on July 24, 2025, reporting as a foreign private issuer. The filing indicates that the company will file its annual reports unde
• Pharvaris N.V. Files Routine 6-K Report — 6-K · 2025-07-10T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on July 10, 2025, reporting for the month of July 2025. The company, previously known as Pharvaris, B.V., is incorporated in the
• Pharvaris N.V. Files June 2025 6-K Report — 6-K · 2025-06-27T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on June 27, 2025, to report on its activities for the month of June 2025. The filing indicates that the company is a foreign pri
• Pharvaris N.V. Files June 2025 6-K Report — 6-K · 2025-06-10T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on June 10, 2025, to report information for the month of June 2025. The filing indicates that Pharvaris N.V. is a foreign privat
• Pharvaris N.V. Files May 2025 6-K Report — 6-K · 2025-05-13T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on May 13, 2025, reporting for the month of May 2025. The company, incorporated in the Netherlands, is a pharmaceutical preparat
• 20-F Filing — 20-F · 2025-04-07T00:00:00.000Z [neutral]
• Pharvaris N.V. Files January 2025 6-K Report — 6-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on January 13, 2025, reporting for the month of January 2025. The company, incorporated in P7 and headquartered in Leiden, The N
• Pharvaris N.V. Files 6-K Report — 6-K · 2024-11-13T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on November 13, 2024, to report information for the month of November 2024. The company, previously known as Pharvaris, B.V., is
• Pharvaris N.V. Files September 2024 6-K Report — 6-K · 2024-09-25T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on September 25, 2024, reporting for the month of September 2024. The company, previously known as Pharvaris, B.V., is incorpora
• Pharvaris N.V. Files Routine 6-K Report — 6-K · 2024-09-23T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on September 23, 2024, for the month of September 2024. The company, a foreign private issuer, is based in Leiden, The Netherlan
• Pharvaris N.V. Files September 2024 6-K Report — 6-K · 2024-09-05T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on September 5, 2024, reporting for the month of September 2024. The company, previously known as Pharvaris, B.V., is incorporat
• Pharvaris N.V. Files 6-K with Q2 2024 Financial Updates — 6-K · 2024-08-14T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a 6-K report on August 14, 2024, detailing financial information as of June 30, 2024. The filing includes data related to various financial
• Pharvaris N.V. Files June 2024 6-K Report — 6-K · 2024-06-28T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on June 28, 2024, to report on its activities for the month of June 2024. The filing indicates that the company is a foreign pri
• Pharvaris N.V. Announces 2024 Annual General Meeting — 6-K · 2024-06-11T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on June 11, 2024, announcing its Annual General Meeting (AGM) of Shareholders. The meeting is scheduled for July 10, 2024, and w
• Pharvaris N.V. Files June 2024 6-K Report — 6-K · 2024-06-04T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on June 4, 2024, to report information for the month of June 2024. The company is a foreign private issuer and files annual repo
• Pharvaris N.V. Files 6-K Update — 6-K · 2024-05-08T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on May 8, 2024, reporting its status as a foreign private issuer. The company, incorporated in the Netherlands, is providing an
• Pharvaris N.V. Files 2023 Annual Report — 20-F · 2024-04-10T00:00:00.000Z [neutral] Risk: medium
  Pharvaris N.V. filed its 20-F for the fiscal year ending December 31, 2023. The company, a pharmaceutical preparations firm, reported financial data including a
• Pharvaris N.V. Files March 2024 6-K Report — 6-K · 2024-03-06T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. filed a Form 6-K on March 6, 2024, to report its activities for the month of March 2024. The company, a pharmaceutical preparations firm based in
• Pharvaris N.V. Files 6-K, Confirms Foreign Private Issuer Status — 6-K · 2024-02-16T00:00:00.000Z [neutral] Risk: low
  Pharvaris N.V. (NASDAQ: PHVS) filed a 6-K on February 16, 2024, indicating it is a foreign private issuer submitting reports under Form 20-F. The filing updates
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• FMR LLC & Abigail Johnson Trim Pharvaris Stake to 9.989% — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: medium
  FMR LLC, a major investment firm, and its Chair and CEO, Abigail P. Johnson, have updated their ownership stake in Pharvaris N.V. (formerly Pharvaris B.V.). As
• LSP V Coöperatieve U.A. Amends Pharvaris N.V. Stake Reporting — SC 13G/A · 2024-02-08T00:00:00.000Z [bearish] Risk: medium
  LSP V Coöperatieve U.A. filed an amended SC 13G/A on February 8, 2024, indicating a change in their ownership of Pharvaris N.V. Ordinary Shares as of December 3
• Pharvaris N.V. Enters Registration Rights Agreement — 6-K · 2024-02-07T00:00:00.000Z [bearish]
  Pharvaris N.V. filed a 6-K on February 7, 2024, announcing it entered into a registration rights agreement on February 5, 2024. This agreement allows certain sh
• venBio Amends Pharvaris N.V. Ownership Filing, Updates Event Dates — SC 13D/A · 2024-01-25T00:00:00.000Z [neutral]
  venBio Global Strategic Fund III, L.P. and its affiliates, including Corey Goodman and Robert Adelman, filed an amendment (SC 13D/A) on January 25, 2024, updati
• Bain Capital Life Sciences Maintains Significant Stake in Pharvaris N.V. — SC 13G/A · 2024-01-22T00:00:00.000Z [neutral]
  Bain Capital Life Sciences Fund, L.P. filed an amended SC 13G/A on January 22, 2024, indicating their continued significant ownership in Pharvaris N.V. The fili
• Pharvaris N.V. Files 6-K, References Jan 22 Press Release — 6-K · 2024-01-22T00:00:00.000Z [neutral]
  On January 22, 2024, Pharvaris N.V. filed a 6-K report with the SEC, indicating they issued a press release on the same day. This filing is a routine update for
• Pharvaris N.V. Files 6-K for Jan 5 Press Release — 6-K · 2024-01-08T00:00:00.000Z [neutral]
  Pharvaris N.V. filed a 6-K on January 8, 2024, to announce a press release issued on January 5, 2024. This filing indicates that the company is providing update